New mesothelioma trial scheduled to begin shortly at the Cardiff University to test the new vaccine, mesothelioma cancer.
Researchers at the University of Cardiff and Velindre Cancer Centre in Cardiff have in the past, in partnership with Oxford, England-based Oxford Biomedica to study immunotherapy of cancer vaccine company called TroVax. According to Eric Butchart pioneer Butchart staging system, which was the first staging system should be developed to detect cancer mesothelioma vaccine offers hope for mesothelioma cancer research. Mr. Butchart spent time working with a team of research
The Mesothelioma cancer, like any other diagnosis cancer cells do not die out, but continue to spread to other areas of the body.
TroVax works, the development of the patient's immune system. The study of lead researcher, Dr. Zsuzsanna tabi Cardiff University recently found that mesothelioma tumor cells, like many other cancer cells express the protein called 5T4. TroVax works by stimulating the patient's body to produce anti-5T4 immune reaction that theoretically then antagonized the any tumor cells carrying the protein 5T4.
Although TroVax has been shown to produce an immune response against other types of cancer cells, phase III trial in kidney cancer vaccine was halted when it was found that the drug improves survival. New study presents first studied TroVax mesothelioma. TroVax will be studied in combination with standard chemotherapeutic drugs for mesothelioma, Alimta and cisplatin.
New therapeutic are especially important for mesothelioma, because it's so aggressive and because there are so few options now available for patients. Currently, most mesothelioma patients are processed in combination with chemotherapy, surgery and radiation. Even with these drugs is modest and forecast life expectancy may be less than 18 months.
Immunotherapy drugs like TroVax may offer new hope for hard-to-treat cancers like mesothelioma. American biotech company Dendreon recently became the first company to win FDA approval for the vaccine against cancer. They produce Provenge for prostate cancer.
The British study is funded by TroVax June Hancock mesothelioma Research Foundation. No details were released on how this new study will be financed or whether it will continue to use TroVax.
Sources:
Oxford Biomedica Announces Joint phase I/II study to evaluate TroVax mesothelioma ", 24 June 2010, ADVFN, news service for London Stock Exchange.
Oxford Biomedica collaborates with cancer immunologists for TroVax in phase I/II study in mesothelioma "RTT news, StockMarketsReview.com.
Last update received, Eric g Butchart retired, Department of kardiotorakal?noj surgery, University Hospital of Wales, Cardiff, United Kingdom
